Equillium shares surge 11.43% intraday after regaining Nasdaq compliance with 10 consecutive days above $1, removing delisting risk.
ByAinvest
Tuesday, Dec 23, 2025 10:33 am ET1min read
EQ--
Equillium surged 11.43% intraday, as the company regained compliance with Nasdaq’s minimum stock price requirement after 10 consecutive trading days above $1, eliminating delisting risk. The firm focuses on developing novel therapies for severe autoimmune and inflammatory diseases, currently advancing its clinical-stage drug EQ504.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet